MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
12.33
+0.09
+0.74%
Pre Market: 12.88 +0.55 +4.46% 08:00 10/04 EDT
OPEN
12.49
PREV CLOSE
12.24
HIGH
12.84
LOW
12.12
VOLUME
3.19K
TURNOVER
--
52 WEEK HIGH
42.11
52 WEEK LOW
9.59
MARKET CAP
847.53M
P/E (TTM)
-4.5746
1D
5D
1M
3M
1Y
5Y
Editas Medicine started at neutral at BofA due to competition in gene editing programs
BofA Securities has initiated Editas Medicine with a neutral rating saying that the company's hemoglobinopathies gene editing candidates face stiff competition. The firm has an $18 price target (~34% upside based on Wednesday's clo...
Seekingalpha · 5d ago
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades
Benzinga · 5d ago
B of A Securities Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $18
B of A Securities analyst Greg Harrison initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Neutral rating and announces Price Target of $18.
Benzinga · 5d ago
Editas Medicine Shares Fall After BofA Securities Begins Coverage at Neutral
Editas Medicine Shares Fall After BofA Securities Begins Coverage at Neutral
MT Newswires · 5d ago
BofA Securities Starts Editas Medicine at Neutral With $18 Price Target
BofA Securities Starts Editas Medicine at Neutral With $18 Price Target
MT Newswires · 5d ago
Intellia falls as analysts react to CRISPR readouts
Gene-editing company Intellia Therapeutics, Inc. (NASDAQ:NTLA</spa...
Seekingalpha · 09/16 16:16
Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:32
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Confer...
GlobeNewswire · 09/01 10:30
More
About EDIT
Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.